Antibiotics are associated with decreased progression-free survival of advanced melanoma patients treated with immune checkpoint inhibitors
Arielle Elkrief(Centre Hospitalier de l’Université de Montréal), Bertrand Routy(Centre Hospitalier de l’Université de Montréal), Wiam Belkaïd(Université de Montréal), Wilson H. Miller(Jewish General Hospital), Meriem Messaoudene(Centre Hospitalier de l’Université de Montréal), Layal El Raichani(Centre Hospitalier de l’Université de Montréal), Philip Wong(Unknown), Rahima Jamal(Centre Hospitalier de l’Université de Montréal), Julie Malo(Université de Montréal), Corentin Richard(Centre Georges François Leclerc), Karl Bélanger(Centre Hospitalier de l’Université de Montréal), Nathalie Letarte(Centre Hospitalier de l’Université de Montréal)
Cited by 207
Related Papers
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
|Science|2017|5.4k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
A Review of Cancer Immunotherapy: From the Past, to the Present, to the Future
|Current Oncology|2020|941
Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells
|Nature Immunology|2017|639